Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 receptor agonist
Semaglutide is a synthetic peptide that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a natural gut hormone involved in blood sugar regulation and appetite signaling. It is available as an injectable and, in one formulation, as an oral tablet.
How it works
Research describes semaglutide as binding to GLP-1 receptors, which are found in the pancreas, brain, and gastrointestinal tract. Published studies report that this stimulates insulin release in a glucose-dependent manner, slows gastric emptying, and acts on brain regions associated with appetite. These mechanisms are how researchers explain its observed effects on blood glucose and food intake.
Researched uses
- Studied for glycemic control in type 2 diabetes
- Studied for chronic weight management in adults with obesity or overweight
- Studied for reducing cardiovascular risk in adults with type 2 diabetes and established heart disease
- Studied for reducing major cardiovascular events in adults with obesity and established cardiovascular disease
- Studied in ongoing research for conditions such as non-alcoholic steatohepatitis and chronic kidney disease
FDA-approved as branded products. Ozempic (subcutaneous) and Rybelsus (oral) are approved for type 2 diabetes. Wegovy (subcutaneous) is approved for chronic weight management. These are prescription-only. Compounded semaglutide has been dispensed by licensed compounding pharmacies during periods of FDA-recognized shortage, under specific regulatory conditions and a valid prescription. Compounded versions are not FDA-approved products, and their availability is tied to shortage status and applicable regulations, which can change.
Semaglutide providers compared
Providers that have passed our rubric review are listed first, then ordered by the total cost of a 3-month protocol. We average every cost to a standard 3-month protocol, which our medical advisors consider the best basis for comparing cost and value, and the headline figure folds in any one-time consult or provider-review fee plus three months of membership. Use the calculator below to adjust the length and see the same total broken out.
Swipe sideways for prices
| Provider | Sourcing | What's included | Verified | Visit provider | |
|---|---|---|---|---|---|
RxPepsDirectVerified Semaglutide/B12 | 503A pharmacy | $114 for 3 months (est.) ≈3 vials · $25/vial incl. $39 consult | Consult fee extra · no membership | Jul 8, 2026 vial price | View |
We average every cost to a standard 3-month protocol, which our medical advisors consider the best window for comparing cost and value. Monthly plans are multiplied by 3 and 3-month programs are taken as billed; each provider's own sticker price and cadence are shown underneath.
The headline figure is the total 3-month cost: the medication plus any one-time consult or provider-review fee (for example RxPepsDirect's $39) and three months of any membership fee. Where a fee is not published we fold in what is known and flag that other fees may apply.
Per-vial providers are averaged to a 3-month protocol at roughly one vial per month (3 vials), marked "est.", with the per-vial price shown underneath. Actual vial count depends on your dose and protocol.
Prices are gathered from each provider's public pages. The "Verified" date is when we last checked the provider's sticker price; for per-vial providers it is the vial price that was verified, not the averaged 3-month total.
Value check: total cost of therapy
This is the real value comparison. A sticker price hides consult and membership fees, so this adds everything up for a full protocol of Semaglutide and ranks by true total cost. We default to a 3-month protocol, the window our medical advisors consider best for judging value.
Per-vial providers are estimated at about one vial per month (3 vials for 3 months), plus any one-time consult. Actual vial count depends on your dose and protocol, so the real cost may run higher or lower.
Price watch: Semaglutide
Get one email when a verified provider's Semaglutide price drops or a safety flag is raised. Nothing else.
Safety notes
Clinical trials reported gastrointestinal side effects most commonly, including nausea, vomiting, diarrhea, and constipation. Labeling includes a boxed warning about thyroid C-cell tumors observed in rodent studies; relevance to humans is not determined. Reported risks also include pancreatitis, gallbladder problems, and hypoglycemia when combined with certain other agents. For compounded versions, product quality, identity, and potency are not verified by the FDA and can vary; only products dispensed through the licensed pharmacy system with a prescription are subject to standard oversight.
Semaglutide questions
How much does Semaglutide cost?
Across the licensed providers tracked here, a full 3-month protocol of Semaglutide totals $114 to $114, depending on the provider, dose, and what is included. We average every cost to a standard 3-month protocol, which our medical advisors consider the best basis for comparing cost and value, and the total folds in any one-time consult or provider-review fee and three months of membership. The providers listing Semaglutide sell it by the vial, so the 3-month figure is an estimate of about one vial per month; the exact vial count depends on your dose and protocol. Each price shows the date the provider's sticker price was verified.
Is semaglutide FDA-approved?
Yes. It is approved as branded prescription products: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. Compounded semaglutide is a separate, non-FDA-approved category that some licensed pharmacies have dispensed during recognized shortages.
What is the difference between the branded and compounded versions?
Branded products are FDA-approved and manufactured under regulated conditions. Compounded semaglutide is prepared by compounding pharmacies and is not FDA-approved. Its availability depends on shortage status and applicable law, and its quality is not verified by the FDA.
How do cost and access typically work?
Access generally requires a prescription and a clinical evaluation. Costs vary widely depending on the specific product, formulation, insurance coverage, and pharmacy. Coverage for weight-management indications differs from coverage for diabetes and varies by plan.
Related reading
- What the SUSTAIN OPTIMIZE trial reported about semaglutide added to reduced insulinA 40-week phase 3b trial compared adding once-weekly semaglutide to a reduced dose of insulin glargine against titrating insulin glargine alone in adults with type 2 diabetes and overweight. The semaglutide group showed larger reported reductions in HbA1c, body weight, and daily insulin dose, with fewer severe low-blood-sugar events but more gastrointestinal complaints.
- What a review of GLP-1 drugs for metabolic problems in schizophrenia reportedA systematic review and meta-analysis pooled seven randomized trials of semaglutide and other GLP-1 receptor agonists in adults with schizophrenia who take antipsychotics. It reported reductions in body weight and some glucose measures, but the authors rated the certainty of evidence as low to moderate.
- A small study comparing weight management approaches during fertility-sparing endometrial cancer careA prospective observational study of 53 patients compared sleeve gastrectomy, semaglutide therapy, and a structured lifestyle program during fertility-sparing treatment for endometrial cancer. It reported differences in weight loss, weight regain, and tumour response over two years.
- Where peptide regulation stands and how to read it as a buyerA practical guide for readers comparing licensed, prescription-based providers, covering the legal status of several widely discussed peptides, how they reach patients through pharmacies, what shapes their cost, and how to evaluate a provider.
- How to prepare for a doctor visit about peptide therapyA practical guide to the legal status, pharmacy availability, and cost drivers behind semaglutide, tirzepatide, tesamorelin, and thymosin-alpha-1, plus how to vet a licensed provider before you book.
- What the evidence gap means when you shop for peptidesA practical guide for readers comparing licensed providers, covering the very different regulatory and availability status of semaglutide, tirzepatide, tesamorelin, semax, and thymosin-alpha-1.
- What the FDA's peptide restrictions mean if you are comparing providersA plain look at where BPC-157, CJC-1295, semaglutide, tirzepatide, and thymosin alpha-1 stand with regulators, how each is legitimately available, and what to ask before you trust a provider.
- What the peptide regulatory shuffle means when you compare licensed providersA plain look at where BPC-157, semaglutide, CJC-1295, and ipamorelin sit legally, how each is or is not available through licensed pharmacies, and how to vet a provider before you commit.
- How to evaluate a legitimate GLP-1 providerA practical look at the legal status of GLP-1 medications, how they reach patients through licensed pharmacies, what shapes the price, and the questions that separate a real provider from a risky one.
- What a retatrutide side effects roundup can and cannot tell youRo published a piece summarizing retatrutide side effects reported in clinical trials. The headline is thin, so here is how to read it without overreaching.
- How small changes to a GLP-1 molecule shifted its signaling in the labA Cell Reports study used protein engineering, cryo-electron microscopy, and diet-induced obese mice to examine how modifying the front end of GLP-1 agonists changes which cellular pathway the receptor favors. The work is mechanistic and preclinical, not a human trial.
- What a review says about GLP-1 medicines in people aging with HIVA review in Current Opinion in HIV and AIDS gathered emerging evidence on GLP-1 receptor agonists such as semaglutide in people with HIV. It reported associations with weight, blood sugar, and fat changes, while flagging open questions about lean mass, bone health, and older populations.
- What a mouse study reported about semaglutide and blood-brain barrier repair after brain injuryResearchers used a mouse model of traumatic brain injury to examine how semaglutide affected blood vessel formation and blood-brain barrier integrity. The study describes a signaling cascade in animals and does not establish anything about outcomes in people.
- What Medicare does and does not cover for GLP-1 weight loss drugsA plain look at how Medicare treats GLP-1 medications, why coverage hinges on the diagnosis rather than the drug, and what that means when you compare licensed prescription providers.
- The thyroid warning on GLP-1 labels and what it means when you compare providersThe medullary thyroid cancer warning appears on FDA-approved GLP-1 labels, and understanding its origin helps you ask better questions. This piece explains the regulatory status of these drugs, how they are legitimately dispensed, what drives cost, and how to vet a licensed provider.
- Zepbound and Ozempic compared as a purchasing decision, not a health claimA plain look at how these two brand-name GLP-1 medications differ in legal status and legitimate availability, and what a reader should weigh when choosing a licensed provider.
- Your smartwatch flagged possible sleep apnea. What a licensed provider can and cannot offerA wearable notification is a prompt to see a clinician, not a diagnosis or a treatment plan. This piece explains how prescription-based care is legitimately accessed, what drives cost, and how to vet a provider without falling for marketing.
- Where BPC-157, semaglutide, and the growth hormone peptides actually stand with regulatorsA plain look at the legal status of five commonly discussed peptides and what that means when you compare licensed, prescription-based providers.
- How the evidence behind a peptide shapes how you can legally buy itThe strength and type of clinical evidence behind a peptide affects its regulatory status, whether a licensed pharmacy can dispense it, and what you pay. Here is how that plays out for four commonly discussed compounds.
- How to tell if a peptide is legitimately availableA practical look at what separates FDA-approved peptides from investigational ones, how each named compound reaches patients through licensed pharmacies, and what to ask before you commit to a provider.
- Peptides are not steroids, and the legal path to getting them looks nothing alikeA practical look at how semaglutide, tirzepatide, tesamorelin, and other named peptides are legally available, what shapes their cost, and how to check that a provider is legitimate.
- How to prepare for a peptide conversation with a licensed providerA practical guide for readers comparing prescription-based providers, covering the legal status of common peptides, how each is legitimately available through licensed pharmacies, what shapes cost, and how to vet a clinic before you commit.
- How the evidence level for a peptide shapes what you can legally buyA practical guide for comparing licensed providers when the peptides on the menu range from FDA-approved drugs to investigational compounds. Focus on legal status, pharmacy availability, cost drivers, and vetting.
- How to check whether peptide information holds up before you pick a providerA practical guide to evaluating peptide claims by starting with regulatory status, legitimate pharmacy availability, and cost, using semaglutide, tirzepatide, tesamorelin, and thymosin-alpha-1 as examples.
- Peptides are not steroids, and the legal path to each one differsPeptides and anabolic steroids sit in different legal and regulatory categories, which changes how each is prescribed, where it can be dispensed, and what a legitimate provider looks like. Here is how the named peptides stand today and how to vet the pharmacy behind them.
- How to prepare for a doctor visit about peptidesA practical guide for patients comparing legal, prescription-based peptide providers, covering the regulatory status of semaglutide, tirzepatide, tesamorelin, and thymosin alpha-1, how each is legitimately obtained, and what to ask before you commit.
- Evidence levels differ by peptide, and so does legal accessA quick guide for readers comparing licensed providers: where semaglutide, tirzepatide, tesamorelin, thymosin alpha-1, and semax sit on the regulatory map, and how that shapes legitimate access and cost.
- What a review of incretin drugs and doxorubicin heart injury in animals foundA systematic review pooled 13 rodent studies testing GLP-1 and dual GIP/GLP-1 drugs during doxorubicin chemotherapy and reported signals of preserved heart function in animals. No human studies met the criteria, and the authors call the findings hypothesis-generating.
- A phase 2 trial of zalfermin plus semaglutide in liver fibrosis from MASHIn a 52-week randomised trial of 698 people with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, adding zalfermin to semaglutide did not significantly outperform placebo on liver fibrosis improvement, while semaglutide alone showed a nominally significant effect versus placebo.
- What a mouse study reported about vutiglabridin combined with GLP-1 medicationsResearchers tested an experimental oral compound called vutiglabridin alongside GLP-1 receptor agonists in obese mice and reported continued fat loss beyond the point where semaglutide alone had leveled off. This was an animal study, and its findings do not establish anything for people.
- Will insurance cover compounded GLP-1 medication?In almost every case, compounded semaglutide and tirzepatide are cash pay, because insurers reimburse FDA-approved products dispensed through standard pharmacy channels. This guide explains why, and the narrow situations where any coverage tends to apply.
- How to check peptide information before you pick a providerA practical guide to verifying what you read about semaglutide, tirzepatide, tesamorelin, and thymosin-alpha-1, and to confirming which are legitimately available through licensed pharmacies.
- Peptides and steroids are not the same category, and the legal status shows itA practical look at how the peptides often confused with steroids actually reach patients through licensed pharmacies, what their regulatory status is, and how to compare providers.
- How to prepare for a peptide conversation with your doctorA practical guide to the legal status, pharmacy availability, and cost drivers behind semaglutide, tirzepatide, tesamorelin, and thymosin alpha-1 so you can compare licensed providers on facts rather than hope.
- What microdosing GLP-1s means for someone comparing providersA practical look at what the term microdosing usually implies, the legal status of the GLP-1 medications involved, and how to evaluate a licensed provider without relying on marketing language.
- How to evaluate GLP-1 providers if you are exploring fertility and metabolic careA practical guide for anyone comparing licensed, prescription-based GLP-1 providers in the context of polycystic ovary syndrome and insulin resistance. It covers regulatory status, legitimate pharmacy access, what drives cost, and questions to ask before you commit.
- What happens at a peptide telehealth consultA walk through a legitimate telehealth flow for peptides, from intake and labs to the prescription decision and refills.
- What a GLP-1 subscription actually includesA breakdown of the parts that make up a telehealth GLP-1 subscription, from the consult and membership to labs and shipping, and why the advertised monthly number rarely matches what you pay.
- How to check that a peptide pharmacy is actually licensedA practical walkthrough of state board lookups, the difference between 503A and 503B pharmacies, and the warning signs that separate a real licensed pharmacy from a research-chemical seller.
- How to Get Peptides Safely and LegallyHow to get peptides through the legal, licensed pathway: prescriptions, 503A/503B pharmacies, honest evidence, and how to avoid the research-use-only gray market.
- Is Peptide Therapy Right for You?An independent guide to weighing peptide therapy: legality, what the research actually shows, who should avoid it, and how to find safe, licensed care.
- Peptides and GLP-1s for Weight ManagementAn independent look at GLP-1s and peptides for weight management: what the research shows, honest limits, safety, legality, and finding licensed care.
- The Compounded Semaglutide Crackdown, ExplainedWhat the FDA's move to end compounded semaglutide means, what the research actually shows, and how to find GLP-1 care inside the licensed pharmacy system.
- Peptide Access in 2026: What's Legal, What's RestrictedAn independent look at peptide access in 2026: which compounds are legal, which are restricted, what the evidence shows, and how to find licensed treatment.
- Peptide Therapy Side Effects: An Evidence-Based GuideAn independent, evidence-based look at peptide therapy side effects by compound class, gray-market supply risk, and how to find safe, legal treatment.
- Why Isn't My GLP-1 Working?Why your GLP-1 may not seem to be working: what research shows about varied response, differences between agents, and how to find safe, legal care.